Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488059 | 0.83 | ACHE (0.44) | ACHEPTPN1NR3C1NR3C2MAPT | |
| SCHEMBL129762 | 0.77 | ACHE (0.57) | ACHEPTPN1NR3C1NR3C2MAPT | |
| SCHEMBL16487758 | 0.76 | ACHE (0.39) | ACHEPTPN1NR3C1NR3C2RAPGEF4 | |
| SCHEMBL13256220 | 0.71 | ACHE (0.46) | ACHEPTPN1MAPTL3MBTL1TAS1R3 | |
| SCHEMBL459763 | 0.71 | ALDH1A1 (0.36) | ACHEMAPTALDH1A1 | |
| SCHEMBL258728 | 0.70 | MAPT (0.35) | ACHEMAPTL3MBTL1RAPGEF4ALDH1A1 | |
| SCHEMBL258715 | 0.70 | MAPT (0.35) | ACHEMAPTL3MBTL1RAPGEF4ALDH1A1 | |
| SCHEMBL13083360 | 0.69 | ACHE (0.48) | ACHEPTPN1NR3C1NR3C2MAPT | |
| SCHEMBL10196604 | 0.69 | ACHE (0.76) | ACHEPTPN1MAPTL3MBTL1 | |
| SCHEMBL532886 | 0.68 | TRPV4 (0.41) | ACHENR3C1NR3C2L3MBTL1RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165771-A1 | PROCESS FOR TREATING KERATIN FIBERS USING PARTICULAR AMINO ACIDS IN HIGH CONCENTRATION | L'OREAL (FR) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165771-A1 | PROCESS FOR TREATING KERATIN FIBERS USING PARTICULAR AMINO ACIDS IN HIGH CONCENTRATION | KRT18, CKAP4, VIM | ACHE 3912/4885PTPN1 4092/4885NR3C1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.